Asheville, NC (July 19, 2016) – Avadim Technologies, Inc. (“ATI”), a life sciences company delivering Pathogenesis Based Therapies (“PBTs”), which work to optimize the stratum corneum, integumentary functions and the associated reactive tissue, announced today an exclusive agreement with GR Match LLC (GRM), an affiliate of Guthy-Renker LLC to help launch ATI’s consumer brands . Guthy-Renker is one of the world’s largest and most respected direct marketing companies for consumer products, well known for building brands such as IT Cosmetics®, Meaningful Beauty® and others.
Avadim’s proven breakthrough platform technology has demonstrated strong outcomes in multiple clinical applications in U.S. hospitals. Now, through this new partnership, Avadim will be able to accelerate the availability of the company’s suite of therapies to the consumer, through Guthy Renker’s proven, best-in-class direct-to-consumer marketing strategies.
Stephen Woody, Chairman and CEO, stated, “Our core stratum corneum technology allows for multiple therapies for consumers. We are pleased to begin working on a consumer driven marketing strategy with a firm of the stature of Guthy-Renker who has a long successful history of representing great brands and selling billions of dollars in products. Together with GRM, we intend to launch many consumer products that leverage our technology for new verticals. We look forward to start marketing our first line of products with the GRM team in early 2017.”
Boris Shimanovsky, President of GRM, commented, “Avadim has tremendous potential. We look forward to working in partnership with the Avadim team as we introduce these innovative products through our established consumer channels”.
About Guthy-Renker:
Guthy-Renker is one of the world’s largest and most respected direct marketing companies. Since 1988, Guthy-Renker has discovered and developed dozens of high quality consumer products in the beauty, skincare and wellness categories. Known for moving, award-winning productions and marketing campaigns featuring some of today’s leading celebrities, the company has been credited with transforming the broadcast direct marketing industry.
About Avadim Technologies, Inc.:
Avadim Technologies, Inc. is a life sciences company that has developed a new class of life sciences solutions based on Pathogenesis Based Therapies (“PBTs”) which work to optimize the stratum corneum, integumentary functions and the associated reactive tissue. Our platform of therapies works to protect and support natural physiological functions of the outer barrier of the body, to super normalize it, supporting treatments within our three series of therapies for infection prevention, neuromuscular disorders and barrier repair. Our platform and technologies use a targeted topical delivery system, are non-toxic and are effective without the side effects of other remedy approaches. Initial acceptance in the U.S. clinical market of our first PBTs and our novel preventative approach, have shown both cost avoidance and superior effectiveness in addressing specific needs in healthcare. Avadim’s advanced therapeutic class of Pathogenesis Based Therapies is capable of unlocking pathways to address emerging gaps in global health.
For more information on Avadim, visit www.avadimhealth.com
Avadim Technologies Inc. Contacts:
Joe McGuire, Chief Financial Officer
828.251.7111 Office
904.228.2603 Cell
David Fann, President
828.251.7111 Office
904.251.4910 Cell
Investor Relations:
Capital Markets Group, LLC
914.669.0222
[email protected]
www.CapMarketsGroup.com